Get the Stockscreener App
27.65
0.61%
-0.17
Pre-market:
27.29
-0.36
-1.30%
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics (NASDAQ:BEAM) Shares Up 8%Still a Buy? - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat
What is HC Wainwright's Estimate for BEAM FY2026 Earnings? - MarketBeat
(BEAM) Long Term Investment Analysis - Stock Traders Daily
Brokers Set Expectations for BEAM Q1 Earnings - MarketBeat
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com India
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com Australia
HC Wainwright Reaffirms "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpWhat's Next? - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for BEAM Earnings - MarketBeat
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
(BEAM)Analyzing Beam Therapeutics's Short Interest - Benzinga
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares - Simply Wall St
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM) - MSN
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Beam Therapeutics (NASDAQ:BEAM) Raised to "Overweight" at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral -January 29, 2025 at 07:29 am EST - Marketscreener.com
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet - Yahoo Finance
Is it a Good Idea to Invest in Beam Therapeutics Stock Now? - MSN
Leerink Partnrs Issues Optimistic Forecast for BEAM Earnings - Defense World
(BEAM) Investment Report - Stock Traders Daily
FY2024 Earnings Estimate for BEAM Issued By Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts BEAM FY2025 Earnings - Defense World
Research Analysts Issue Forecasts for BEAM FY2025 Earnings - MarketBeat
Beam Therapeutics to present updated BEAM-101 trial data - Investing.com India
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - The Manila Times
Beam Therapeutics to present updated BEAM-101 trial data By Investing.com - Investing.com UK
Beam Therapeutics to Encore Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics' BEAM-101 Shows Strong Results in Sickle Cell Disease Trial Data - StockTitan
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Beam Therapeutics Shares Cross Above 200 DMA - Nasdaq
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts - Seeking Alpha
50,285 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by Avanza Fonder AB - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones - MSN
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Shares Down 8%Should You Sell? - MarketBeat
Beam Therapeutics’ (BEAM) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Given Outperform Rating at Wedbush - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Down 8%Time to Sell? - MarketBeat
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? - MSN
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates By Investing.com - Investing.com South Africa
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates - Investing.com India
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):